• Pharma Fights Back With New Reputation-saving Campaign

    Feature Articles by on April 10th, 2017

    Earlier this year, the Pharmaceutical Research and Manufacturers of America (PhRMA) launched a national, multi-year advertising and public affairs initiative on behalf of America’s biopharmaceutical companies with the aim of rebuilding the industry’s reputation by showcasing its “unsung heroes”—the researchers leading cutting-edge medical and scientific discoveries. The multimillion dollar campaign, tilted GOBOLDLY, will consist of […]

  • Answer Patients’ Burning Questions about Prescriptions

    Feature Articles by on April 10th, 2017

    Big pharma has a trust problem on its hands. The $600 EpiPen. Shkreli’s greedy misconduct. Soaring co-pays. Patients are as aggravated as you are with the bleak headlines surrounding the state of healthcare. Today, just 9% of Americans believe pharmaceutical companies put patients over profits.1 Pharma’s addiction to outdated marketing models compounds these problems. Over-reliance […]

  • A Manufacturer’s Perspective: Optimizing Market Access for a New Orphan Drug

    We recently prepared for the launch of an HCP-administered therapy for patients with an orphan oncology condition and high unmet need. Our goal was to ensure that every patient who needed the therapy would have rapid and unburdened access upon approval. This is not an easy challenge for a HCP-administered therapy that payers are expected […]

  • Putting the Patient Back into Clinical Trials

    Feature Articles by on April 10th, 2017

    The pharmaceutical industry is witnessing a deep shift in the traditional approach to patient disclosure in clinical trials. While most companies are struggling to meet basic compliance requirements, a longer-term objective has emerged that is shifting the transparency goal post. Clinical trial results information is typically disclosed on registries such as ClinicalTrials.gov and EudraCT. This […]

  • Using Predictive Analytics to Enhance Customer Interaction

    Feature Articles by on March 17th, 2017

    Getting data to help us better interact with our customers is something we all strive to do. Historically, the pharmaceutical industry has used the abundant data it collects on doctor prescribing, patient claims, outlet sales, rep calls, marketing promotional spend, managed care formulary—and the list goes on to address business problems centered on brand performance […]

  • The Intervention-Environment Matrix for Predictive Analytics

    Feature Articles by on March 17th, 2017

    Predictive analytics efforts can significantly impact commercial success by optimizing sales and marketing efforts. Commercial leaders experienced in the utilization of predictive analytics will have developed a good sense of where predictive analytic efforts can be deployed most effectively and with the highest probability of success. For organizations with little experience in this area, however, […]

  • Navigating the Challenges of Prescription Affordability

    Feature Articles by on March 17th, 2017

    Regardless of the future of the ACA, prescription affordability has been and will continue to be a significant issue in American healthcare. Looking ahead, two important players in the healthcare mix—payers and the new Trump administration—will likely exert more pressure on pharmaceutical companies to lower the cost of branded medications. Just as important, physicians and […]

  • Meeting the Targets of Triple Aim

    Feature Articles by and on March 17th, 2017

    For quite some time healthcare costs have stood firmly in the crosshairs of lawmakers, care advocates, and cash-strapped patients—and not without reason. Obamacare was intended to dampen the growth of healthcare costs, while increasing quality of care and expanding access. However, at 28% of the 2017 U.S. federal budget, healthcare is the largest expense, nearly […]

  • Risk/Outcomes Contracting Has Finally Arrived

    Feature Articles by on February 24th, 2017

    In our organization’s payer market research, we generally find pharmacy and medical directors respond to proposed risk- or outcomes-based contracting with muted interest. The reasons often include cost of contract management, lack of internal staff and infrastructure to extract and report the data, and inconsistent data availability across their membership. Among insurers and networks, electronic […]

  • Avoid the Price Crisis

    Feature Articles by on February 24th, 2017

    Reputational crisis. This is the best expression to describe the worsening relationship between the biopharmaceutical industry and the very people it seeks to serve. Today, companies that make medicines to save or improve peoples’ lives are less respected than law firms and oil companies.1 One study even shows that the number of Americans who believe […]

  • Making Step Therapy Work for Patients, Providers, and Payers

    Feature Articles by on February 24th, 2017

    The use of step therapy protocols by payers to manage pharmacy costs has increased significantly over the past several years. According to Health Strategies Group, in 2015, 39% of health plans used step therapy in at least 12 classes of medications—an increase of 35% over the prior year. At its core, step therapy is about […]

  • Overcoming the Challenges of Step Therapy

    Feature Articles by on February 24th, 2017

    Step therapy, or “fail first” as it is sometimes called, requires patients to first attempt treatment with one drug before the payer will allow coverage of the treatment initially prescribed by the physician. Payers implement these protocols as a way to manage costs by first steering a patient to a generic or formulary-preferred drug. This […]

  • Healthcare 2017: A New Day is Dawning

    The results of the recent presidential election caught many by surprise, including much of the healthcare industry. Given her track record as First Lady, Senator, and Secretary of State, many felt they knew what to expect from a Clinton administration and were building plans for it. However, a Trump win has left many wondering what […]

Back to top